What is HC Wainwright’s Forecast for KYTX FY2027 Earnings?

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Equities researchers at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Kyverna Therapeutics in a note issued to investors on Monday, March 30th. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($2.67) per share for the year. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share.

Several other equities research analysts also recently commented on KYTX. Wells Fargo & Company boosted their target price on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, Morgan Stanley set a $33.00 price target on shares of Kyverna Therapeutics in a research report on Monday, December 15th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Kyverna Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $28.67.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ:KYTX opened at $8.77 on Tuesday. The company has a debt-to-equity ratio of 0.11, a current ratio of 7.75 and a quick ratio of 7.75. The business’s fifty day moving average price is $8.25 and its two-hundred day moving average price is $7.70. Kyverna Therapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $13.67. The stock has a market capitalization of $384.13 million, a price-to-earnings ratio of -2.40 and a beta of 2.60.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Thursday, March 26th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80).

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of KYTX. Empowered Funds LLC acquired a new stake in shares of Kyverna Therapeutics in the 4th quarter valued at $169,000. Quadrature Capital Ltd acquired a new position in shares of Kyverna Therapeutics during the fourth quarter valued at $539,000. Millennium Management LLC lifted its stake in shares of Kyverna Therapeutics by 7.6% during the fourth quarter. Millennium Management LLC now owns 593,369 shares of the company’s stock valued at $5,578,000 after acquiring an additional 41,734 shares during the period. Balyasny Asset Management L.P. bought a new position in Kyverna Therapeutics in the fourth quarter valued at about $9,220,000. Finally, 683 Capital Management LLC bought a new position in Kyverna Therapeutics in the fourth quarter valued at about $1,080,000. 18.08% of the stock is currently owned by institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.